Aflunov (zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted))

Region: 🇪🇺 EU
Active substance: zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Company: Seqirus S.r.l.
Status: Authorised
Therapeutic area: Influenza, Human; Immunization; Disease Outbreaks
EU approval: Sun 28 Nov 2010
Application: EMEA/H/C/002094
ATC: J07BB02
Official record: www.ema.europa.eu

Indication

Active immunisation against H5N1 subtype of Influenza A virus in individuals 6 months of age and above. Aflunov should be used in accordance with official recommendations.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

🇪🇺 Celldemic Authorised · Seqirus Netherlands B.V.

Follow Aflunov

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.